OPEN END TURBO SHORT - BRISTOL-MYERS SQUIBB | Market Closed - Börse Stuttgart 20:48:07 20/06/2024 BST | ||
| 1.69 EUR | 0.00% |
|
| Current month | +1.20% | ||
| 1 month | +17.36% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 20/06/24 | 1.69 | 0.00% |
| 19/06/24 | 1.69 | -1.17% |
| 18/06/24 | 1.71 | +1.18% |
| 17/06/24 | 1.69 | +1.81% |
| 14/06/24 | 1.66 | +1.22% |
Delayed Quote Börse Stuttgart
Last update June 20, 2024 at 08:48 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | Morgan Stanley |
| WKN | ME2UXR |
| ISIN | DE000ME2UXR9 |
| Date issued | 31/10/2023 |
| Strike | 59.12 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.84 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.75 € |
|---|---|
| Lowest since issue | 0.46 € |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.04
USD
Average target price
53.19
USD
Spread / Average Target
+29.62%
- Stock Market
- Certificates
- Certificat
